Abstract
This paper reviews the need for risk management in pharmaceutical industry research and development and the analytical procedures available for that purpose. These are shown to be inadequate. We propose two new measures of risk which are illustrated with the use of current pharmaceutical research and development (R&D) data. Our most important findings are twofold: that risk quantification in pharmaceutical R&D today often does not capture the full extent of a company's exposure to financial risk, and that better methods such as our new risk measures can and should be developed. We hope that our work both in this literature review and in the creation of new risk measures will inspire companies to take a closer look at their current R&D management strategies, and to refresh and update their risk mitigation policies accordingly.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
